Search any drug on the FDA's active shortage list for an estimated discontinuation risk, and the reasoning behind it.
Among drugs already on the FDA's shortage list, an estimate of whether the listing ends in a permanent discontinuation, or resolves as a temporary gap.
A gradient-boosted model trained on public openFDA shortage records, validated with combination-grouped cross-validation (~0.93 AUC on unseen drug profiles). Supplier concentration is the dominant signal, alongside dosage form and therapeutic category — cross-checked by a separate survival analysis: low-supplier shortages reach a final determination in a median of ~260 days, versus years for the rest.
A signal to support your own judgment, not a certainty. Some categories rest on small sample sizes, and only drugs currently shortage-listed are indexed — this doesn't predict which drugs go into shortage next. Not a substitute for official FDA guidance.
Shortage and discontinuation records reflect information reported to the FDA and are for informational purposes only. For the most current supply status of a specific product, contact the manufacturer directly.